ARA-290 (Cibinetide) Dosage Protocol Guide: Innate Repair Receptor Agonist Reconstitution & Research (2026)

> Research Use Only Disclaimer: ARA-290 (Cibinetide) is an investigational compound that has not received FDA or EMA marketing approval for any indication. All dosing and protocol information presented here is derived from published clinical research and is provided strictly for educational purposes. This content does not constitute medical advice. Consult a licensed healthcare professional before considering any experimental compound.

ARA-290, commercially known as Cibinetide, is an 11-amino-acid synthetic peptide engineered from the helix-B surface of erythropoietin (EPO). Unlike native EPO, it was deliberately designed to eliminate erythropoietic activity while retaining the tissue-protective and anti-inflammatory signaling mediated by the innate repair receptor (IRR) — the EPOR/CD131 heterodimeric complex. This unique separation of function makes ARA-290 one of the most clinically studied non-hematopoietic peptides in neuropathy research.

With FDA Orphan Drug Designation for neuropathic pain in sarcoidosis and for sarcoidosis itself, ARA-290 has accumulated more human trial data than most research peptides in the neuroprotection space. This guide covers the validated dosing protocols drawn from Phase 2 clinical trials, practical reconstitution procedures, and the administration details researchers need to implement ARA-290 protocols accurately.

For a comprehensive overview of ARA-290's mechanism of action, clinical evidence, and research applications, see the ARA-290 (Cibinetide) Complete Research Profile.

---

What is ARA-290 (Cibinetide)?

ARA-290 is a helix-B surface peptide — an 11-amino-acid sequence corresponding to residues 11, 14–17, and 58–65 of human erythropoietin. It was developed by Araim Pharmaceuticals (now Cibinetide) specifically to activate the innate repair receptor (IRR) without triggering the classical EPOR homodimer that drives red blood cell production.

The IRR (EPOR/β-common receptor heterodimer) is expressed throughout peripheral nerve tissue, the central nervous system, pancreatic β-cells, retinal cells, and cardiac tissue. Activation of this receptor initiates JAK2/STAT signaling pathways linked to neuroprotection, anti-apoptosis, reduced neuroinflammation, and regeneration of small fiber nerve endings.

Because ARA-290 bypasses the classical EPO receptor homodimer entirely, it produces none of the erythropoietic side effects — elevated hematocrit, thrombotic risk, or cardiovascular strain — that limit EPO's use as a therapeutic agent. Hemoglobin and hematocrit levels remained statistically unchanged across all ARA-290 clinical trials.

---

Clinical Trial Dosing: The Evidence Base

ARA-290 has undergone multiple Phase 2 clinical trials, providing human dosing data that is unusually robust for an investigational peptide. The validated dosing protocols are:

Intravenous Protocol (Phase 2a — Sarcoidosis/SFN)

In the earliest human trial, patients received:

• •Dose: 2 mg intravenously (IV)
• •Frequency: Three times per week
• •Duration: 4 weeks

This trial demonstrated significant improvement in the Small Fiber Neuropathy Screening List (SFNSL) score versus placebo (p < 0.05), establishing ARA-290's capacity to reduce neuropathic symptoms. IV administration carries a half-life of approximately 2 minutes, which drove the shift to subcutaneous dosing in subsequent trials.

Subcutaneous Protocol (Phase 2b — Primary Research Dose)

The pivotal Phase 2b multicenter RCT (n=64) established the standard research protocol:

• •Dose: 4 mg subcutaneously (SC)
• •Frequency: Once daily
• •Duration: 28 days

This 28-day daily SC protocol is the most replicated and widely referenced in the research literature. Primary endpoints demonstrated:

• •Significantly increased corneal nerve fiber area (p=0.012)
• •Increased GAP-43-positive regenerating intraepidermal nerve fibers (p=0.035)
• •Objective nerve fiber regeneration confirmed by corneal confocal microscopy

Diabetic Neuropathy Protocol (Phase 2)

A parallel Phase 2 randomized trial used the same 4 mg SC daily x 28-day protocol in patients with type 2 diabetes and peripheral neuropathy. Results through day 56 showed:

• •Improved neuropathic symptom scores (PainDetect questionnaire)
• •Increased corneal nerve fiber density
• •Improved HbA1c and lipid profiles versus placebo

Extended Research Protocol (12-Week Duration)

A Phase 2 study in diabetic macular edema applied the 4 mg SC daily protocol for 12 consecutive weeks, establishing tolerability data for longer-duration use. No serious adverse events were reported.

---

Pharmacokinetics

Understanding ARA-290's pharmacokinetic profile is essential for protocol design:

The short half-life (~20 minutes subcutaneously) appears counterintuitive given the sustained 24-hour+ effects observed in trials. Researchers hypothesize that rapid receptor occupancy followed by downstream JAK2/STAT signaling cascades produces effects that outlast circulating peptide concentration — analogous to how brief hormone pulses can trigger prolonged gene expression changes.

This pharmacokinetic profile supports once-daily rather than multiple-daily dosing, as receptor-level downstream effects persist far beyond plasma detection limits.

---

Vial Sizes and Reconstitution

Common Vial Formats

ARA-290 is supplied as lyophilized (freeze-dried) powder in sealed vials. Research-grade suppliers typically offer:

Step-by-Step Reconstitution Protocol

Materials required:

• •Lyophilized ARA-290 vial
• •Bacteriostatic water for injection (BAC water)
• •1 mL or 3 mL sterile syringes
• •25–27 gauge needles
• •Alcohol swabs
• •Refrigeration storage

Procedure:

1. Temperature equilibration: Remove the ARA-290 vial from −20°C storage and allow it to reach room temperature for 10–15 minutes. Reconstituting cold powder increases the risk of aggregation.

2. Surface sterilization: Wipe the rubber stopper of both the ARA-290 vial and the BAC water vial with fresh alcohol swabs. Allow to dry completely before piercing.

3. Water draw: Using a fresh syringe, draw the appropriate volume of bacteriostatic water (see table above). Expel any air bubbles by tapping the syringe and pressing the plunger gently.

4. Injection technique — critical step: Insert the needle through the rubber stopper at a 45-degree angle, directing the tip toward the glass wall rather than the center of the powder mass. Inject the BAC water slowly down the inside wall of the vial. Injecting directly onto the lyophilized cake creates shear forces that can fragment the peptide structure.

5. Mixing: Remove the needle. Gently roll the vial between your palms or swirl slowly. Do not vortex or shake vigorously — mechanical disruption can cause aggregation and denaturation.

6. Visual inspection: The reconstituted solution should be clear and colorless to pale yellow. Do not use if cloudy, particulate matter is visible, or the solution has a strong odor.

7. Labeling: Mark the vial with the reconstitution date and store immediately at 2–8°C, protected from light.

---

Dose Calculation Reference

For research applications using 4 mg/day target dose:

Using a 10 mg/mL solution (10 mg vial + 1 mL BAC water):

• •4 mg ÷ 10 mg/mL = 0.4 mL = 40 units on a U-100 insulin syringe

Using a 5 mg vial + 2 mL BAC water (2.5 mg/mL):

• •4 mg ÷ 2.5 mg/mL = 1.6 mL (requires a 2 mL syringe)
• •For a 2 mg dose: 2 ÷ 2.5 = 0.8 mL = 80 units on a U-100 syringe

Using a 16 mg vial + 2 mL BAC water (8 mg/mL):

• •4 mg ÷ 8 mg/mL = 0.5 mL = 50 units on a U-100 syringe

---

Administration Protocol

Injection Sites

Subcutaneous injection sites validated in clinical trials:

• •Lower abdomen: 2–4 cm lateral to the navel; preferred for consistent absorption
• •Anterior/lateral thigh: Suitable for self-administration
• •Upper arm (lateral): Less commonly used; requires assistance for self-injection

Site rotation is essential to prevent lipodystrophy and maintain consistent absorption. Rotate through a minimum of 4–6 sites on a cycle.

Injection Technique

1. Clean the injection site with an alcohol swab and allow to dry

2. Pinch a fold of skin between thumb and forefinger

3. Insert a 27–29 gauge insulin syringe needle at a 45–90 degree angle (use 45° for lean subjects, 90° for subjects with adequate subcutaneous adipose)

4. Inject slowly over 5–10 seconds — not as a rapid bolus

5. Hold the needle in place for 5 seconds post-injection before withdrawal to prevent tracking

6. Apply gentle pressure with a clean swab; do not rub

Timing

Clinical trials administered injections in the morning (approximately 8–10 AM). No formal study has assessed circadian timing effects for ARA-290 specifically, but morning administration aligns with established peptide research practice and supports protocol consistency.

---

Research Dosing Summary Table

---

Storage Requirements

Pre-Reconstitution (Lyophilized)

• •Temperature: −20°C (−4°F) or lower
• •Stability: 2+ years at −20°C when stored properly
• •Light: Protect from direct light exposure
• •Handling: Minimize freeze-thaw cycling; each cycle degrades peptide integrity

Post-Reconstitution (Liquid)

• •Temperature: 2–8°C (35–46°F) — standard refrigerator
• •Stability window: Use within 14–28 days of reconstitution
• •Protection: Store in an opaque container or wrapped in foil to minimize light exposure
• •Do not freeze reconstituted solution — freezing the liquid form can cause aggregation

---

Safety Profile

ARA-290 has demonstrated a favorable safety profile across multiple human trials, with no serious adverse events attributed to the compound at the 4 mg daily subcutaneous dose. Key safety data points:

Adverse effects reported in trials:

• •Mild injection site reactions (redness, swelling, minor pain) — most common
• •Transient headache — reported in early Phase 2
• •Mild fatigue following first injections — typically resolves within 1–2 weeks
• •Occasional transient nausea — rare

Confirmed absence of erythropoietic effects:

Hemoglobin and hematocrit values remained within normal ranges across all clinical trials, confirming that ARA-290 does not stimulate red blood cell production at research doses.

Contraindications noted in trial protocols:

• •Active malignancy or myeloproliferative disorder (precautionary, given EPO-derived mechanism)
• •Known hypersensitivity to EPO or EPO-derived compounds

Long-term safety: Data beyond 12 weeks of continuous use is not available from controlled clinical trials. The safety profile for extended or repeated use cycles remains uncharacterized.

---

ARA-290 vs. EPO: Key Distinctions

Researchers familiar with erythropoietin sometimes question how ARA-290 differs in practice:

---

Research Applications Summary

Phase 2 clinical trials have investigated ARA-290 in the following contexts:

• •Sarcoidosis-associated small fiber neuropathy (SFN): Strongest clinical evidence; objective nerve regeneration demonstrated via corneal confocal microscopy
• •Diabetic peripheral neuropathy: Improved neuropathic symptoms and metabolic markers in Type 2 diabetes
• •Diabetic macular edema: Safe at 12 weeks; mixed primary endpoint results
• •Cardiac ischemia (preclinical): Reduced infarct size in animal models comparable to EPO without erythropoietic effects
• •Corneal nerve regeneration: Demonstrated increased nerve fiber density as an objective biomarker

---

Key Takeaways for Researchers

1. The validated research dose is 4 mg SC daily for 28 days — this protocol has the strongest clinical evidence base

2. Reconstitution technique matters — inject BAC water down the vial wall slowly; do not shake

3. Short half-life, sustained effect — ~20-minute plasma half-life does not limit once-daily dosing efficacy

4. No erythropoietic risk at research doses — confirmed across multiple RCTs

5. Storage is critical — lyophilized at −20°C; reconstituted at 2–8°C, use within 14–28 days

6. Site rotation — rotate among 4–6 subcutaneous sites to prevent local reactions

7. Not FDA-approved — investigational status; no clinical use outside approved trials

For complete mechanism of action, clinical evidence details, and research context, visit the ARA-290 (Cibinetide) Research Profile.

---

This article is for educational and research purposes only. ARA-290 (Cibinetide) is an investigational compound. This content does not constitute medical advice, diagnosis, or treatment recommendations. For research purposes only. Not for human use.